Impact of pioglitazone and bradykinin type 1 receptor antagonist on type 2 diabetes in high‐fat diet‐fed C57BL/6J mice

AIM: Type 2 diabetes (T2D) is a major complication of obesity and a leading cause of morbidity and mortality. Antagonizing bradykinin type 1 receptor (B1R) improved body and tissue fat mass and reversed vascular and adipose tissue inflammation in a rat model of insulin resistance. This study aimed a...

Descripción completa

Detalles Bibliográficos
Autores principales: El Akoum, S., Haddad, Y., Couture, R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5598024/
https://www.ncbi.nlm.nih.gov/pubmed/29071111
http://dx.doi.org/10.1002/osp4.117

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5598024/
https://www.ncbi.nlm.nih.gov/pubmed/29071111
http://dx.doi.org/10.1002/osp4.117

Ejemplares similares